Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.75 USD

77.75
2,585,851

+1.08 (1.41%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $77.76 +0.01 (0.01%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs

by Arpita Dutt

This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.

    Allergan's Vraylar Positive for Bipolar Disease in Phase III

    by Zacks Equity Research

    Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.

      AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA

      by Zacks Equity Research

      AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include treatment of NSCLC with EGFR mutation in first-line setting has been accepted by the FDA.

        Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion

        by Zacks Equity Research

        Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.

          Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

          by Zacks Equity Research

          Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

            Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

            by Zacks Equity Research

            Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.

              Pfizer Reports Updated Data from Phase III Study on Ibrance

              by Zacks Equity Research

              Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.

                Clovis' sNDA for Rubraca Gets Priority Review in the U.S.

                by Zacks Equity Research

                The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.

                  Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

                  by Zacks Equity Research

                  Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

                    AstraZeneca's COPD Drug Succeeds in Label Expansion Study

                    by Zacks Equity Research

                    AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

                      Swarup Gupta headshot

                      Foreign Stock Roundup: Statoil Buys Oil Field Stakes for $1.45B, Shell Resumes Dividend Payment

                      by Swarup Gupta

                      A selloff in tech stocks and a crucial U.S. tax legislation dominated proceedings for Europe's bourses this week.

                        Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug

                        by Zacks Equity Research

                        Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.

                          Cancer Space Update: Pfizer's Bavencio Fails in Phase III

                          by Zacks Equity Research

                          The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.

                            How Will U.S. Tax Reform Impact Pharma/Biotech Industry?

                            by Zacks Equity Research

                            After certain modifications to the original plan over the past year, the tax reform bill is expected to be voted on by the Congress this week. Let's see how this vote will impact the pharma/biotech industry.

                              AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

                              by Zacks Equity Research

                              AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

                                AstraZeneca Files for Label Expansion of Tagrisso in Japan

                                by Zacks Equity Research

                                AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

                                  2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17

                                  by Zacks Equity Research

                                  Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.

                                    Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

                                    by Zacks Equity Research

                                    Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.

                                      Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU

                                      by Zacks Equity Research

                                      This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.

                                        Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry

                                        by Zacks Equity Research

                                        Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.

                                          3 Companies Competing to Gain Lead in Ovarian Cancer Market

                                          by Zacks Equity Research

                                          Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

                                            by Arpita Dutt

                                            Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

                                              Parkinson's Space in Focus as Acorda Stops Tozadenant Trial

                                              by Zacks Equity Research

                                              Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.

                                                Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

                                                by Zacks Equity Research

                                                Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.

                                                  TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU

                                                  by Zacks Equity Research

                                                  TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.